61.79
price up icon3.51%   2.115
 
loading

Belite Bio Inc Adr Aktie (BLTE) Neueste Nachrichten

pulisher
08:00 AM

Belite Bio Executives Share Latest Retinal Disease Breakthroughs at BTIG Biotech Conference - Stock Titan

08:00 AM
pulisher
Jul 21, 2025

New Strong Sell Stocks For July 22nd - Barchart.com

Jul 21, 2025
pulisher
Jul 19, 2025

What analysts say about Belite Bio Inc Depositary Receipt stockConsistent wealth multiplication - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 16, 2025

Belite Bio concludes enrollment for phase 3 GA trial on oral tinlarebant - Eyes On Eyecare

Jul 16, 2025
pulisher
Jul 16, 2025

Stargardt Disease Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Nanoscope Therapeutics, Belite Bio, Biophytis, reVision Therapeutics, Inc - The Globe and Mail

Jul 16, 2025
pulisher
Jul 15, 2025

Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Solid Biosciences (SLDB) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail

Jul 15, 2025
pulisher
Jul 11, 2025

Q2 EPS Estimates for Belite Bio Decreased by Leerink Partnrs - Defense World

Jul 11, 2025
pulisher
Jul 10, 2025

Ouster Announces Date for Second Quarter 2025 Earnings Call - The Globe and Mail

Jul 10, 2025
pulisher
Jul 09, 2025

Belite Bio, Inc.’s Tinlarebant: Promising Treatment for Stargardt Disease with Significant Market Potential - TipRanks

Jul 09, 2025
pulisher
Jul 08, 2025

Phase 3 PHOENIX trial for oral GA treatment completes enrollment - Modern Retina

Jul 08, 2025
pulisher
Jul 03, 2025

Belite Bio stock maintains Buy rating at H.C. Wainwright on trial progress - Investing.com India

Jul 03, 2025
pulisher
Jul 02, 2025

Belite Bio Completes Enrollment for Phase 3 PHOENIX Trial on Tinlarebant - TipRanks

Jul 02, 2025
pulisher
Jul 02, 2025

Positive Buy Rating for Belite Bio Driven by Phase 3 PHOENIX Trial Milestone and Regulatory Designations - TipRanks

Jul 02, 2025
pulisher
Jun 12, 2025

Analysts Issue Forecasts for Belite Bio FY2026 Earnings - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Reviewing Belite Bio (NASDAQ:BLTE) & ZyVersa Therapeutics (NASDAQ:ZVSA) - Defense World

Jun 11, 2025
pulisher
Jun 07, 2025

Bank of America Corp DE Acquires 4,891 Shares of Belite Bio, Inc (NASDAQ:BLTE) - Defense World

Jun 07, 2025
pulisher
Jun 07, 2025

Cohen & Company Inc. (NYSEAMERICAN:COHN) Stock Price Crosses Above Two Hundred Day Moving Average – Here’s What Happened - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

Belite Bio, Inc (NASDAQ:BLTE) Shares Sold by Citadel Advisors LLC - Defense World

Jun 05, 2025
pulisher
May 31, 2025

BNP Paribas Financial Markets Acquires New Shares in Belite Bio, Inc (NASDAQ:BLTE) - Defense World

May 31, 2025
pulisher
May 24, 2025

What is HC Wainwright’s Forecast for Belite Bio Q1 Earnings? - Defense World

May 24, 2025
pulisher
May 23, 2025

What is HC Wainwright's Estimate for Belite Bio Q2 Earnings? - MarketBeat

May 23, 2025
pulisher
May 22, 2025

Belite Bio stock holds $80 target on FDA breakthrough nod By Investing.com - Investing.com Nigeria

May 22, 2025
pulisher
May 22, 2025

Belite Bio stock holds $80 target on FDA breakthrough nod - Investing.com

May 22, 2025
pulisher
May 22, 2025

Belite Bio’s Promising Outlook: FDA Breakthrough Designation and Upcoming Milestones Boost Buy Rating - TipRanks

May 22, 2025
pulisher
May 21, 2025

Yi Chen Recommends Buy Rating for Belite Bio Due to Breakthrough Therapy Designation and Promising Trial Progress - TipRanks

May 21, 2025
pulisher
May 21, 2025

Why Belite Bio’s Stock is Soaring High - TipRanks

May 21, 2025
pulisher
May 21, 2025

Belite Bio’s Tinlarebant Receives FDA Breakthrough Therapy Designation for Stargardt Disease - TipRanks

May 21, 2025
pulisher
May 21, 2025

Belite Bio Says FDA Grants Breakthrough Therapy Tag to Stargardt Disease Drug - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

Belite Bio Announces FDA Granting Of Breakthrough Therapy Designation For Tinlarebant For The Treatment Of Stargardt Disease - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

Belite Bio Receives FDA Breakthrough Therapy Designation for Tinlarebant in Treating Stargardt Disease - Nasdaq

May 21, 2025
pulisher
May 21, 2025

Belite Bio Announces FDA Granting of Breakthrough Therapy - GlobeNewswire

May 21, 2025
pulisher
May 20, 2025

Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA), Arcellx Inc (ACLX) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail

May 20, 2025
pulisher
May 19, 2025

Q2 Earnings Estimate for Belite Bio Issued By HC Wainwright - Defense World

May 19, 2025
pulisher
May 17, 2025

Belite Bio (NASDAQ:BLTE) Earns “Overweight” Rating from Cantor Fitzgerald - Defense World

May 17, 2025
pulisher
May 17, 2025

HC Wainwright Reaffirms Buy Rating for Belite Bio (NASDAQ:BLTE) - Defense World

May 17, 2025
pulisher
May 16, 2025

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - GlobeNewswire

May 16, 2025
pulisher
May 16, 2025

Benchmark maintains Buy on Belite Bio stock, $80 price target unchanged - Investing.com Nigeria

May 16, 2025
pulisher
May 15, 2025

Belite Bio’s Earnings Call Highlights Clinical Progress and Financial Strength - TipRanks

May 15, 2025
pulisher
May 15, 2025

Belite Bio at Deutsche Bank Conference: Promising Drug Trials By Investing.com - Investing.com India

May 15, 2025
pulisher
May 15, 2025

Transcript : Belite Bio, Inc Presents at Deutsche Bank ADR Virtual Investor Conference, May-15-2025 12 - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

Belite Bio at Deutsche Bank Conference: Promising Drug Trials - Investing.com

May 15, 2025
pulisher
May 15, 2025

Belite Bio stock retains Overweight rating at Cantor Fitzgerald - Investing.com Australia

May 15, 2025
pulisher
May 15, 2025

Belite Bio stock retains Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com India

May 15, 2025
pulisher
May 15, 2025

Promising Clinical Trials and Strategic Developments Justify Buy Rating for Belite Bio - TipRanks

May 15, 2025
pulisher
May 15, 2025

Belite Bio Advances Clinical Trials Amid Financial Challenges - TipRanks

May 15, 2025
pulisher
May 14, 2025

Earnings call transcript: Belite Bio’s Q1 2025 sees narrower EPS loss - Investing.com Nigeria

May 14, 2025
pulisher
May 14, 2025

Earnings Flash (BLTE) Belite Bio Q1 Loss $0.45 Vs. FactSet Est. $0.35 Loss - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Belite Bio Q1 2025 Earnings Call Transcript - MarketBeat

May 14, 2025
pulisher
May 14, 2025

Belite Bio Advances Tinlarebant Trials with Positive Interim Results - TipRanks

May 14, 2025
pulisher
May 14, 2025

Belite Bio, Inc Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 14, 2025
pulisher
May 13, 2025

Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update - ADVFN

May 13, 2025
pulisher
May 13, 2025

Belite Bio reports Q1 EPS (45c), consensus (37c) - TipRanks

May 13, 2025
pulisher
May 13, 2025

Belite Bio's Stargardt Disease Drug Passes Critical Phase 3 Trial Review, DSMB Suggests Regulatory Filing - Stock Titan

May 13, 2025
pulisher
May 12, 2025

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025 - GlobeNewswire Inc.

May 12, 2025
pulisher
May 12, 2025

Why Cigna Group Stock Dived Today - The Globe and Mail

May 12, 2025
pulisher
May 12, 2025

Belite Bio, Inc to Present at the dbVICDeutsche Bank ADR Virtual Investor Conference May 15th - GlobeNewswire

May 12, 2025
$22.82
price up icon 4.70%
$36.02
price down icon 0.21%
$102.84
price down icon 0.10%
$27.88
price up icon 5.26%
$113.83
price up icon 2.13%
biotechnology ONC
$294.77
price down icon 0.27%
Kapitalisierung:     |  Volumen (24h):